PolyPid (NASDAQ:PYPD) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $14.00 price objective on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.48) EPS and Q4 2025 earnings at ($0.40) EPS.

PolyPid Stock Up 4.8 %

Shares of PolyPid stock opened at $5.00 on Wednesday. The company’s 50-day moving average price is $4.96 and its 200-day moving average price is $5.02. The company has a debt-to-equity ratio of 2.17, a current ratio of 0.83 and a quick ratio of 0.83. PolyPid has a 12-month low of $3.57 and a 12-month high of $13.48.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, February 14th. The company reported ($3.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.17) by ($1.80). As a group, research analysts expect that PolyPid will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Rosalind Advisors Inc. purchased a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 415,800 shares of the company’s stock, valued at approximately $1,913,000. PolyPid comprises approximately 1.8% of Rosalind Advisors Inc.’s portfolio, making the stock its 20th biggest position. Rosalind Advisors Inc. owned about 8.67% of PolyPid at the end of the most recent quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.